Oral Semaglutide: How It Works, Doses, Side Effects, and How It Compares to Injectables

How does the tablet work?

Semaglutide is a GLP-1 receptor agonist: a GLP-1 analogue with 94% sequence homology to human GLP-1. It binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake, and it delays gastric emptying [1]. In the injected form its half-life is about one week [1].

The hard part is absorption. The tablet is co-formulated with SNAC (salcaprozate sodium), an absorption enhancer. In dog and clinical studies, semaglutide was absorbed in the stomach, in a small area close to the tablet surface, and absorption required SNAC. SNAC protects the peptide from enzymatic breakdown by buffering locally and enhances absorption only briefly. The route was transcellular, and the investigators found no evidence that SNAC works by opening tight junctions [4].

Bioavailability stays low: about 1% to 2% for the Wegovy tablet versus 89% for subcutaneous semaglutide, which is why tablet and injection doses in milligrams cannot be swapped [1]. Per the labels, the tablets are taken once daily in the morning on an empty stomach with up to 4 ounces of plain water, swallowed whole, with a wait of at least 30 minutes before food, other drinks or other oral medicines [1][2]. The Wegovy tablet label says a missed dose is skipped and the next dose taken the following day [1].

Which oral semaglutide products exist?

• Rybelsus (approved 2019-09-20): 3, 7 and 14 mg tablets. Indicated to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk [2][5].
• Ozempic tablets: 1.5, 4 and 9 mg, under the same approval and the same two indications. Rybelsus and Ozempic tablets are not substitutable milligram for milligram [2].
• Wegovy tablets (approved 2025-12-22): 1.5, 4, 9 and 25 mg, for adults only. Indicated to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, and to reduce excess weight and maintain the loss in adults with obesity, or overweight plus a weight-related condition [1][6].

Two limits matter. The Wegovy tablet label gives no pediatric or MASH indication and says the tablets were not studied for weight reduction in adults with type 2 diabetes [1]. And the Wegovy label does not recommend using Wegovy with another semaglutide-containing product or any other GLP-1 receptor agonist [1].

Doses and the step-up schedule

Rybelsus: 3 mg once daily for 30 days (this dose is not effective for glycemic control), 7 mg from day 31 to day 60, then 7 or 14 mg from day 61 [2].

Ozempic tablets: 1.5 mg once daily for 30 days (not effective for glycemic control), 4 mg from day 31 to day 60, then 4 or 9 mg [2].

Wegovy tablets: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, then 25 mg from day 91 [1]. For someone moving from the Wegovy 2.4 mg injection, tablets start one week after the last injection [1].

The labels describe the slow escalation as a way to reduce gastrointestinal adverse reactions [2].

What the weight-loss trial shows

The approved 25 mg tablet was tested in a 71-week double-blind trial with primary endpoints at week 64: 307 adults with a BMI of 30 or higher, or 27 or higher with a weight-related complication, and no diabetes, took oral semaglutide 25 mg (205 people) or placebo (102 people). Mean weight change was -13.6% versus -2.2%, a difference of 11.4 percentage points, and gastrointestinal adverse events were reported in 74.0% versus 42.2% [3]. The Wegovy label presents the same study as Study 7, with at least 20% weight loss in 27.9% versus 3.1% [1].

A 50 mg oral dose was also tested. In OASIS 1, 667 adults without diabetes were randomized to oral semaglutide 50 mg or placebo for 68 weeks; weight fell 15.1% versus 2.4%, at least 5% loss occurred in 85% versus 26%, and at least 20% loss in 34% versus 3% [7]. That 50 mg dose is not an approved strength.

What the diabetes trials show

In PIONEER 1, 703 adults with type 2 diabetes on diet and exercise alone took oral semaglutide 3, 7 or 14 mg or placebo for 26 weeks. Placebo-adjusted HbA1c reductions were 0.6, 0.9 and 1.1 percentage points, and placebo-adjusted body weight differences were -0.1, -0.9 and -2.3 kg (treatment-policy estimand) [8].

For cardiovascular outcomes, SOUL randomized 9,650 adults aged 50 and older with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, to oral semaglutide up to 14 mg daily or placebo. Over a median of 49.5 months, cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 12.0% versus 13.8% (hazard ratio 0.86, 95% CI 0.77 to 0.96) [9]. This trial is the basis of the cardiovascular indication now on the Rybelsus and Ozempic tablet label [2].

Side effects

Gastrointestinal effects dominate, and they are worst during dose escalation. In pooled placebo-controlled trials of the tablets in type 2 diabetes (362 on placebo, 356 on 7 mg, 356 on 14 mg), nausea occurred in 6%, 11% and 20%; abdominal pain in 4%, 10% and 11%; diarrhea in 4%, 9% and 10%; decreased appetite in 1%, 6% and 9%; vomiting in 3%, 6% and 8%; and constipation in 2%, 6% and 5%. Any gastrointestinal reaction occurred in 21%, 32% and 41%, and 1%, 4% and 8% stopped treatment for a gastrointestinal reason [2].

For the 25 mg weight-management tablet, the label says reaction types and frequencies were similar to the injection table, based on a 64-week trial of 204 adults. Severe gastrointestinal reactions occurred in 2% versus 0% on placebo, altered skin sensation (dysesthesia) in 5% versus 0%, and 6.9% versus 5.9% stopped for adverse reactions [1].

Serious risks on the label

• Thyroid C-cell tumors (boxed warning). Semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures; whether it does so in humans is unknown. Rybelsus, Ozempic tablets and Wegovy tablets carry a boxed warning about thyroid C-cell tumors in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1][2]. The label tells prescribers to inform patients of the symptoms of thyroid tumors: a mass in the neck, trouble swallowing, shortness of breath and persistent hoarseness [1][2].
• Pancreatitis. The label says to discontinue the drug if pancreatitis is suspected [1][2].
• Gallbladder disease. In weight-management trials, cholelithiasis occurred in 1.6% on Wegovy injection versus 0.7% on placebo, cholecystitis in 0.6% versus 0.2%, and cholelithiasis in 2.5% on Wegovy tablets versus 1% [1].
• Hypoglycemia with insulin or a sulfonylurea. The label advises considering a lower dose of the insulin or sulfonylurea when starting. In a 52-week add-on to insulin trial, glucose below 54 mg/dL occurred in 32% on placebo, 26% on Rybelsus 7 mg and 30% on 14 mg [2].
• Kidney injury from dehydration. The tablet label warns that vomiting or diarrhea can lead to dehydration and kidney injury, and calls for kidney-function monitoring when reactions could cause fluid loss [2].
• Diabetic retinopathy. In a pooled analysis of glycemic control trials, retinopathy-related adverse reactions were reported in 4.2% on semaglutide tablets versus 3.8% on comparator, and the label says patients with a history of diabetic retinopathy should be monitored [1][2].
• Pulmonary aspiration during anesthesia or deep sedation. Reported in patients receiving GLP-1 receptor agonists who underwent elective surgeries or procedures; the label says patients should inform their healthcare providers of any planned procedures [2].
• Pregnancy and breastfeeding. The Wegovy label says to discontinue Wegovy when pregnancy is recognized in people using it for weight reduction or cardiovascular risk reduction, and to stop it at least 2 months before a planned pregnancy because of the long half-life [1]. The Rybelsus and Ozempic tablets label likewise says to discontinue at least 2 months before a planned pregnancy because of the long washout period [2]. It also says breastfeeding is not recommended, because SNAC and its metabolites are present in human milk and the potential for serious effects in a breastfed infant is unknown [2].

The Wegovy label also lists mean resting heart rate increases of 1 to 4 bpm [1], and all semaglutide labels say the drug is not recommended in people with severe gastroparesis [1][2].

Drug interactions

Semaglutide tablets raised levothyroxine total exposure by 33% (90% CI 1.25 to 1.42) in a drug interaction study, and the label advises closer clinical or laboratory monitoring for oral drugs with a narrow therapeutic index [2]. No clinically significant effect was seen on lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin, and omeprazole did not change semaglutide levels [1].

The semaglutide labels carry no advice to switch or add a barrier method for oral contraceptives, unlike the tirzepatide and orforglipron labels [1][10][11].

How does it compare with the injection?

Both contain semaglutide, but delivery differs. The injection reaches the blood at about 89% bioavailability and is given once weekly at any time of day, with or without meals; the tablet is about 1% to 2% bioavailable and must be taken fasting [1].

On weight, the numbers from separate trials land close. The 25 mg tablet gave 13.6% loss at week 64 in 205 treated adults [3]. The 2.4 mg Wegovy injection gave 14.9% versus 2.4% at 68 weeks in 1,961 adults [12], and the injection now goes higher: 7.2 mg weekly produced 18.7% loss versus 15.6% on 2.4 mg and 3.9% on placebo in STEP UP (1,407 adults, 72 weeks) [13]. These are separate trials with different populations and durations, and none of them compared the tablet with the injection directly. Wegovy tablets were not studied for weight reduction in adults with type 2 diabetes [1]; in STEP 2, adults with type 2 diabetes on the 2.4 mg weekly injection lost 9.6% of body weight versus 3.4% on placebo [14].

On cardiovascular risk, both routes have outcome data: SOUL for the tablet up to 14 mg (12.0% versus 13.8%, hazard ratio 0.86) [9] and SELECT for the 2.4 mg injection in adults with cardiovascular disease and overweight or obesity but no diabetes (6.5% versus 8.0%, hazard ratio 0.80) [15]. Different populations, so the sizes of the effects are not comparable.

Gastrointestinal rates also cannot be lined up. The tablet figures come largely from diabetes trials at 7 and 14 mg, the injection figures from weight trials at 2.4 mg, and the labels themselves state that adverse reaction rates from different trials cannot be compared directly [1][2].

What about tirzepatide and other oral GLP-1 pills?

Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist and is injection-only [11]. In the open-label SURMOUNT-5 trial of 751 adults with obesity, tirzepatide at the maximum tolerated dose produced 20.2% weight loss versus 13.7% for injectable semaglutide at 1.7 or 2.4 mg over 72 weeks [16]. SURMOUNT-5 compared tirzepatide with injectable semaglutide, not the tablet [16].

Oral GLP-1 therapy is no longer semaglutide alone. Orforglipron (Foundayo) was approved on 2026-04-01 as an oral GLP-1 receptor agonist for weight reduction in adults, taken once daily with or without food [10][17]. In the 52-week ACHIEVE-3 trial of 1,698 adults with type 2 diabetes, HbA1c fell 1.91 points on orforglipron 36 mg and 1.47 points on oral semaglutide 14 mg [18].